{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:00:33Z","timestamp":1793545233954,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Internal research grant: Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA63\/016"],"award-info":[{"award-number":["RA63\/016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Preterm birth is a major challenge in obstetric and perinatal care. It is the leading cause of neonatal death. The primary aim of this study was to evaluate the efficacy of oral dydrogesterone on latency period in managing preterm labor. The secondary aims were to evaluate the gestational age at delivery, percentage of preterm delivery before 34 weeks and 37 weeks, time to recurrent uterine contraction, pregnancy outcomes, neonatal outcomes, compliance and side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a randomized, double blinded, placebo-controlled trial. Forty-eight pregnant women with preterm labor, singleton pregnancy, and gestational age of 24\u201334 weeks were enrolled into the study. The study group received 10\u00a0mg of oral dydrogesterone three times per day and the control group received placebo. All pregnant women received standard treatment with tocolytic and antenatal corticosteroids.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The\u00a0median latency periods were not significantly different between the dydrogesterone group (27.5 days) and placebo group (34 days,<jats:italic>p<\/jats:italic>= 0.45). Additionally, there were no differences in the gestational age at delivery, percentage of preterm delivery before 34 weeks and 37 weeks, pregnancy outcomes, neonatal outcomes, compliance and side effects. However, the time to the recurrence of uterine contractions in participants that had recurrent preterm labor was\u00a0longer in the dydrogesterone group than in the placebo group (30.6 \u00b1 12.3 vs 13.7 \u00b1 5.0 days,<jats:italic>p<\/jats:italic>= 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Adjunctive treatment with 30\u00a0mg of oral dydrogesterone could not prolong latency period in preterm labor when compared to placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov (Clinical trials registration:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03935152\">NCT 03935152<\/jats:ext-link>, registered on May 2,2019).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12884-021-03562-6","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T13:06:26Z","timestamp":1611839186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral dydrogesterone as an adjunctive therapy in the management of preterm labor: a randomized, double blinded, placebo\u2010controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Suparudeewan","family":"Thongchan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vorapong","family":"Phupong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"issue":"10063","key":"3562_CR1","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/S0140-6736(16)31593-8","volume":"388","author":"L Liu","year":"2016","unstructured":"Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016;388(10063):3027\u201335.","journal-title":"Lancet"},{"key":"3562_CR2","doi-asserted-by":"crossref","unstructured":"Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, Kinney M, Lawn J, Action BTSPB. Born Too Soon: The global epidemiology of 15 million preterm births. Reprod Health. 2013;10Suppl(1):2.","DOI":"10.1186\/1742-4755-10-S1-S2"},{"key":"3562_CR3","volume-title":"Williams obstetrics","year":"2018","unstructured":"Cunningham FG, Lenovo KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, Spong CY, editors. Williams obstetrics. 25th ed. New York: McGraw Hill; 2018.","edition":"25"},{"issue":"4","key":"3562_CR4","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/AOG.0000000000001711","volume":"128","author":"ACOG practice bulletin no","year":"2016","unstructured":"ACOG practice bulletin no. 171: Management of preterm labor. Obstet Gynecol 2016, 128(4):e155-e164.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"3562_CR5","first-page":"60","volume":"4","author":"ER Norwitz","year":"2011","unstructured":"Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol. 2011;4(2):60\u201372.","journal-title":"Rev Obstet Gynecol"},{"issue":"4","key":"3562_CR6","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/AOG.0b013e3182723b1b","volume":"120","author":"Practice bulletin no","year":"2012","unstructured":"Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012, 120(4):964\u2013973.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"3562_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000328719","volume":"72","author":"I Arikan","year":"2011","unstructured":"Arikan I, Barut A, Harma M, Harma IM. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest. 2011;72(4):269\u201373.","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"3562_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1479-828X.2007.00803.x","volume":"48","author":"S Borna","year":"2008","unstructured":"Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: A randomised controlled trial. Aust NZ J Obstet Gynaecol. 2008;48(1):58\u201363.","journal-title":"Aust NZ J Obstet Gynaecol"},{"issue":"1","key":"3562_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijgo.2014.01.019","volume":"126","author":"M Choudhary","year":"2014","unstructured":"Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MMA. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynecol Obstet. 2014;126(1):60\u20133.","journal-title":"Int J Gynecol Obstet"},{"issue":"8","key":"3562_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/1471-0528.14513","volume":"124","author":"A Jarde","year":"2017","unstructured":"Jarde A, Lutsiv O, Park CK, Barrett J, Beyene J, Saito S, Dodd JM, Shah PS, Cook JL, Biringer AB, et al. Preterm birth prevention in twin pregnancies with progesterone, pessary, or cerclage: a systematic review and meta-analysis. BJOG. 2017;124(8):1163\u201373.","journal-title":"BJOG"},{"key":"3562_CR11","doi-asserted-by":"crossref","unstructured":"Areeruk W, Phupong V. A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor. Sci Rep Areeruk W, Phupong V. A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor. Sci Rep. 2016;6:20638.\u00a0","DOI":"10.1038\/srep20638"},{"issue":"1","key":"3562_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/1471-0528.13061","volume":"122","author":"BM de Tejada","year":"2015","unstructured":"de Tejada BM, Karolinski A, Ocampo MC, Laterra C, Hosli I, Fernandez D, Surbek D, Huespe M, Drack G, Bunader A, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG. 2015;122(1):80\u201391.","journal-title":"BJOG"},{"key":"3562_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.lfs.2018.07.004","volume":"207","author":"K Yasuda","year":"2018","unstructured":"Yasuda K, Sumi G, Murata H, Kida N, Kido T, Okada H. The steroid hormone dydrogesterone inhibits myometrial contraction independently of the progesterone\/progesterone receptor pathway. Life Sci. 2018;207:508\u201315.","journal-title":"Life Sci"},{"key":"3562_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.maturitas.2003.09.014","volume":"46","author":"AE Schindler","year":"2003","unstructured":"Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JHH. Classification and pharmacology of progestins. Maturitas. 2003;46:7\u201316.","journal-title":"Maturitas"},{"issue":"1","key":"3562_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijgo.2015.06.058","volume":"132","author":"AC Eke","year":"2016","unstructured":"Eke AC, Chalaan T, Shukr G, Eleje GU, Okafor CI. A systematic review and meta-analysis of progestogen use for maintenance tocolysis after preterm labor in women with intact membranes. Int J Gynecol Obstet. 2016;132(1):11\u20136.","journal-title":"Int J Gynecol Obstet"},{"issue":"1","key":"3562_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12884-017-1400-y","volume":"17","author":"S Wood","year":"2017","unstructured":"Wood S, Rabi Y, Tang S, Brant R, Ross S. Progesterone in women with arrested premature labor, a report of a randomised clinical trial and updated meta-analysis. BMC Pregnancy Childbirth. 2017;17(1):258.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"6","key":"3562_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajog.2007.10.013","volume":"197","author":"N Ruddock","year":"2007","unstructured":"Ruddock N, Shi SQ, Jain S, Moore G, Hankins GDV, Romer R, Garfield R. Progesterone (P4), but not 17alpha hydroxyprogesterone caproate (17P), inhibits human myometrial contractions. Am J Obstet Gynecol. 2007;197(6):6\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"3562_CR18","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/1471-0528.13956","volume":"123","author":"M Palacio","year":"2016","unstructured":"Palacio M, Cobo T, Antolin E, Ramirez M, Cabrera F, de Rosales FM, Bartha JL, Juan M, Marti A, Oros D, et al. Vaginal progesterone as maintenance treatment after an episode of preterm labour (PROMISE) study: a multicentre, double-blind, randomised, placebo-controlled trial. BJOG. 2016;123(12):1990\u20139.","journal-title":"BJOG"},{"issue":"7","key":"3562_CR19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3109\/14767058.2011.629014","volume":"25","author":"DA Bomba-Opon","year":"2012","unstructured":"Bomba-Opon DA, Kosinska-Kaczynska K, Kosinski P, Wegrzyn P, Kaczynski B, Wielgos M. Vaginal progesterone after tocolytic therapy in threatened preterm labor. J Matern Fetal Neonat Med. 2012;25(7):1156\u20139.","journal-title":"J Matern Fetal Neonat Med"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12884-021-03562-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-03562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T19:16:05Z","timestamp":1619118965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-021-03562-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3562"],"URL":"https:\/\/doi.org\/10.1186\/s12884-021-03562-6","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Research Ethics Committee of the Faculty of Medicine, Chulalongkorn University. IRB no. 011\/62.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}